Amunix Pharmaceuticals, Inc. — Form D
Amunix Pharmaceuticals, Inc. of SOUTH SAN FRANCISCO, CA, a company, filed a Form D exempt-offering notice with the SEC on 2021-03-09. The offering totals $117.0M, of which $117.0M was reported sold. Industry: Biotechnology.
Offering
- Filed: 2021-03-09
- Form: D
- Accession: 0001805035-21-000002
- Industry: Biotechnology
- Exemptions: 06b
- Total offering: $117.0M
- Amount sold: $117.0M
- Investors: 28
- Date of first sale: 2021-02-26
- Security types: equity
- Revenue range: Decline to Disclose
- SEC file number: 021-391600
Issuer
- Name: Amunix Pharmaceuticals, Inc.
- CIK: 0001805035
- Entity type: Corporation
- Jurisdiction: DELAWARE
- Address: 2 TOWER PL, #1100, SOUTH SAN FRANCISCO, CA, 94080-1826
- Phone: 650-428-1800
Officers, directors & promoters (9)
| Name | Role | Location |
|---|
| James Brush | Director | South San Francisco, CA |
| Richard Heyman | Director | South San Francisco, CA |
| David Hirsch | Director | San Diego, CA |
| Trisha Millican | Director | South San Francisco, CA |
| Otello Stampacchia | Director | Boston, MA |
| James Topper | Director | La Jolla, CA |
| Angie You | Director | San Diego, CA |
| Volker Schellenberger | Executive Officer | South San Francisco, CA |
| Angie You | Executive Officer | San Diego, CA |
Other filings by this issuer (3)
More